tiprankstipranks
Advertisement
Advertisement
Citizens biotech analysts hold an analyst/industry conference call
PremiumThe FlyCitizens biotech analysts hold an analyst/industry conference call
1M ago
Larimar Therapeutics assumed with a Buy at H.C. Wainwright
Premium
The Fly
Larimar Therapeutics assumed with a Buy at H.C. Wainwright
1M ago
Larimar Therapeutics price target lowered to $5 from $7 at Baird
Premium
The Fly
Larimar Therapeutics price target lowered to $5 from $7 at Baird
1M ago
Larimar stumbles on safety news even as BLA submission kicks off
PremiumThe FlyLarimar stumbles on safety news even as BLA submission kicks off
1M ago
Larimar Advances Nomlabofusp BLA Toward Accelerated Approval
Premium
Company Announcements
Larimar Advances Nomlabofusp BLA Toward Accelerated Approval
1M ago
Larimar Therapeutics submits first module of rolling BLA for nomlabofusp
Premium
The Fly
Larimar Therapeutics submits first module of rolling BLA for nomlabofusp
1M ago
Larimar Therapeutics: Buy Rating Backed by Superior Nomlabofusp Data and Favorable Risk-Reward Versus Design Therapeutics
PremiumRatingsLarimar Therapeutics: Buy Rating Backed by Superior Nomlabofusp Data and Favorable Risk-Reward Versus Design Therapeutics
3M ago
Larimar Therapeutics price target lowered to $12 from $13 at Wedbush
Premium
The Fly
Larimar Therapeutics price target lowered to $12 from $13 at Wedbush
3M ago
Larimar Therapeutics price target lowered to $12 from $13 at Wedbush
Premium
The Fly
Larimar Therapeutics price target lowered to $12 from $13 at Wedbush
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100